Latest Conference Articles

September 8th 2015, 3:40pm

World Conference on Lung Cancer

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

September 8th 2015, 3:28pm

World Conference on Lung Cancer

Most patients younger than age 40 with lung cancer had tumors with mutations that can be targeted with existing therapies.

September 8th 2015, 12:21pm

World Conference on Lung Cancer

Adding bevacizumab (Avastin) to a standard chemotherapy doublet reduced the risk of death by 24% and disease progression by 39% in patients with malignant pleural mesothelioma.

September 7th 2015, 3:58pm

World Conference on Lung Cancer

Ramaswamy Govindan, MD, medical oncologist, Washington University School of Medicine in St. Louis, discusses a talk given at the 16th World Conference on Lung Cancer.

September 7th 2015, 3:05pm

World Conference on Lung Cancer

Patients with newly diagnosed metastatic non-small lung cancer had double the expected response when the PD-L1 inhibitor atezolizumab was added to chemotherapy.

September 7th 2015, 1:42pm

World Conference on Lung Cancer

Everett E. Vokes, MD, chair, Department of Medicine, investigator of head and neck and lung cancer, University of Chicago, discusses a plenary session that covered prevention and screening at the 16th World Conference on Lung Cancer.

September 7th 2015, 1:13pm

World Conference on Lung Cancer

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

July 16th 2015, 2:09pm

ESMO Gastrointestinal Cancers Congress

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

July 15th 2015, 10:43am

ESMO Gastrointestinal Cancers Congress

Yung-Jue Bang, MD, PhD, discusses pembrolizumab for the treatment of advanced gastric cancer. Pembrolizumab was investigated as part of the KEYNOTE-012 study, which looked at the checkpoint inhibitor across several solid tumors.

July 7th 2015, 1:03pm

ESMO Gastrointestinal Cancers Congress

Michael Manns, MD, the Director of the Department of Gastroenterology, Hepatology and Endocrinology at the Medical School of Hannover in Germany, explains risk factors for hepatitis C-related hepatocellular carcinoma.

July 4th 2015, 10:01am

ESMO Gastrointestinal Cancers Congress

Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.

July 4th 2015, 6:25am

ESMO Gastrointestinal Cancers Congress

Howard S. Hochster, MD, professor of Medicine and Associate Director for Clinical Sciences, Yale Cancer Center, discusses the potential of TAS-102 for colorectal cancer.

July 4th 2015, 6:18am

ESMO Gastrointestinal Cancers Congress

The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.

July 4th 2015, 5:36am

ESMO Gastrointestinal Cancers Congress

Lorenza Rimassa, MD, Deputy Director - Medical Oncology Unit - Humanitas Cancer Center, Humanitas Research Hospital, discusses a study looking at tivantinib (ARQ 197), a highly selective MET inhibitor, for the treatment of Metastatic Colorectal Cancer (mCRC).

July 3rd 2015, 3:09pm

ESMO Gastrointestinal Cancers Congress

Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.

July 3rd 2015, 12:11pm

ESMO Gastrointestinal Cancers Congress

TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.

July 3rd 2015, 11:28am

ESMO Gastrointestinal Cancers Congress

Adding an NK1 antagonist to a 5-HT3 receptor antagonist with dexamethasone improved antiemetic control for patients with colorectal cancer treated with an oxaliplatin-based regimen compared with the 5-HT3 antagonist and dexamethasone alone.

July 3rd 2015, 9:11am

ESMO Gastrointestinal Cancers Congress

Andrew Zhu, MD, PhD, Associate Professor, Medicine, Harvard Medical School Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the REACH study, which looks at ramucirumab in advanced hepatocellular carcinoma.

July 3rd 2015, 8:57am

ESMO Gastrointestinal Cancers Congress

Josep Tabernero, MD, PhD, summarized novel agents that are currently under exploration for patients with gastric cancer.

July 3rd 2015, 6:18am

ESMO Gastrointestinal Cancers Congress

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses the safety profile of the phase III B CONSIGN study, which looked at regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).